# OnCo record kinase-inhibitors (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/kinase-inhibitors/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "kinase-inhibitors" ;
  schema:name "Small-molecule kinase inhibitors"@en ;
  schema:description "Pills that block the specific enzyme a cancer relies on. Imatinib in 2001 proved a cancer could be switched off by design."@en ;
  schema:url <https://onco.cc/technologies/kinase-inhibitors/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Tyrosine_kinase_inhibitor> ;
  owl:sameAs <http://www.wikidata.org/entity/Q906415> ;
  schema:citation <https://en.wikipedia.org/wiki/Tyrosine_kinase_inhibitor> ;
  onco:status "standard-of-care" ;
  onco:related <https://onco.cc/technologies/gamma-secretase-inhibitors/>, <https://onco.cc/technologies/hedgehog-inhibitors/>, <https://onco.cc/technologies/her2-tyrosine-kinase-inhibitors/>, <https://onco.cc/technologies/pi3k-akt-mtor-inhibitors/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:targets <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/alk/>, <https://onco.cc/targets/braf/>, <https://onco.cc/targets/kras/>, <https://onco.cc/targets/ret/>, <https://onco.cc/targets/ntrk/>, <https://onco.cc/targets/met/>, <https://onco.cc/targets/fgfr2/>, <https://onco.cc/targets/kit/>, <https://onco.cc/targets/flt3/>, <https://onco.cc/targets/cdk4-6/>, <https://onco.cc/targets/pik3ca/>, <https://onco.cc/targets/akt/> ;
  onco:drugs <https://onco.cc/drugs/fostamatinib/>, <https://onco.cc/drugs/olmutinib/> ;
  onco:companies <https://onco.cc/companies/acrivon-therapeutics/>, <https://onco.cc/companies/alixia/>, <https://onco.cc/companies/altay-therapeutics/>, <https://onco.cc/companies/blueprint-medicines/>, <https://onco.cc/companies/cogent-biosciences/>, <https://onco.cc/companies/enliven-therapeutics/>, <https://onco.cc/companies/erasca/>, <https://onco.cc/companies/fidocure/>, <https://onco.cc/companies/harmonic-discovery/>, <https://onco.cc/companies/ideaya-biosciences/>, <https://onco.cc/companies/nested-therapeutics/>, <https://onco.cc/companies/oric-pharmaceuticals/>, <https://onco.cc/companies/prelude-therapeutics/>, <https://onco.cc/companies/relay-therapeutics/>, <https://onco.cc/companies/reverie-labs/>, <https://onco.cc/companies/scorpion-therapeutics/>, <https://onco.cc/companies/tyra-biosciences/>, <https://onco.cc/companies/velorum-therapeutics/>, <https://onco.cc/companies/zentalis-pharmaceuticals/>, <https://onco.cc/companies/basilea/>, <https://onco.cc/companies/denovo-biopharma/>, <https://onco.cc/companies/arog-pharmaceuticals/>, <https://onco.cc/companies/cyclacel/> ;
  onco:terms <https://onco.cc/terms/oncogene-addiction/>, <https://onco.cc/terms/resistance/> ;
  onco:trials <https://onco.cc/trials/gefitinib-chemo-tmh/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-gainor-alk-resistance-mutations-cancer-discov-2016/>, <https://onco.cc/key-papers/paper-shaw-alk-resistance-mutations-lorlatinib-jco-2019/>, <https://onco.cc/key-papers/paper-oxnard-osimertinib-resistance-mechanisms-jama-oncol-2018/> .